Dear Editors, After kidney transplantation, BK polyomavirus (BKPyV) DNAemia affects approximately 10-30% of recipients. In a subset of these cases (1-10%), BKPyV DNAemia progresses to BK polyomavirus-associated nephropathy (BKPyVAN), marked by renal impairment and the risk of graft failure (1-4). Treatment primarily involves the reduction of immunosuppression since effective antiviral therapy against BKPyV is lacking (5-8). However, a clinical dilemma arises when patients develop biopsy-proven acute rejection (BPAR) following an episode of BKPyV DNAemia. In our experience, clinicians are often hesitant to initiate full immunosuppressive therapy due to concerns about reactivating BKPyV infection. This creates uncertainty about whether a more restrained approach to rejection treatment is warranted in this setting. To explore this, we conducted a single-center, retrospective cohort study including adult kidney transplant recipients (KTRs) transplanted at the Leiden University Medical Center (LUMC) between 2011 and 2020. Patients with primary non-function, multi-organ transplants, missing follow-up data, or participation in investigational immunosuppressive trials were excluded. Patients were categorized into three groups: (1) those with biopsy-proven acute rejection (BPAR) preceded by BKPyV DNAemia (BKPyV-BPAR), (2) those with BPAR occurring ≥6weeks post-transplantation without prior BKPyV DNAemia (BPAR-only), and (3) those without BPAR during follow-up (No-BPAR). The ≥6-week threshold for the BPAR-only group was chosen because BKPyV DNAemia is typically not present before this period. Consequently, rejection episodes occurring from 6-weeks are more likely to be pathophysiological and clinically comparable to those preceded by BKPyV DNAemia. Graft outcomes, including eGFR over time and graft loss at 5 years, were compared between groups. To assess rejection management, we evaluated adherence to our center's treatment protocol. Therapy was considered 'less than protocol' if prescribed doses were reduced or agents were withheld entirely. In addition, to gain insight into potential delays in treatment of rejection, we calculated the time interval between a ≥20% rise in serum creatinine and the initiation of rejection treatment. Data were extracted from the transplantation database, which is directly linked to structured data of electronic health record and pathology department. Data were analyzed using Chi-square test, One-way ANOVA, and linear Mixed-Effects Model (LMM) to assess longitudinal eGFR trends at 6 weeks, 6 months, 1 year, 3 years and 5 years after transplantation. At our center, BKPyV DNAemia is screened at 1.5, 3, 6, and 12 months after kidney transplantation using quantitative real-time PCR on serum samples. If BKPyV DNAemia is detected, monitoring frequency increases to every 2 weeks. For viral loads 10E4 copies/mL, the CNI dose is halved and MMF is discontinued. After two consecutive undetectable serum BKPyV loads, immunosuppression is increased to standard protocol trough levels. BPAR was defined by histopathological assessment according to the Banff classification of the time of biopsy. In cases with suspected BKPyVAN—typically BKPyV DNAemia >4 log copies/mL with rising creatinine—a kidney biopsy was performed. The distinction between TCMR Banff 1A and BKPyVAN can be challenging, as both can present with interstitial inflammation and tubulitis. To reduce misclassification, SV40-staining was systematically applied in biopsies with tubulointerstitial inflammation. A positive SV40-staining in combination with detectable BKPyV DNAemia is considered as BKPyVAN. Whereas negative SV40-staining in combination of undetectable BKPyV DNAemia in the setting of tubilitis favors TCMR. This study was reviewed by the LUMC ethics committee, which concluded that formal approval was not required (ID:131830). A total of 968 KTRs were included in this study. Of these, 870 (89.9%) were classified as No-BPAR, 66 (6.8%) as BPAR-only, and 32 (3.3%) as BKPyV-BPAR. Patients in both rejection groups (BPAR-only and BK-BPAR) were younger, more frequently re-transplanted, and more often immunized (PRA >5%) compared to those in the No-BPAR group. When examining rejection within the groups, mixed rejection was more common in the BKPyV-BPAR group compared to the BPAR-only group (31.3% vs. 10.6%), whereas T-cell mediated rejection (TCMR) was more common in the BPAR-only group ( 74.2% vs. 59.4%),p=0.038. In the BKPyV-BPAR group, BPAR occurred on average 210 ± 429 days after BKPyV DNAemia. With regard to rejection treatment, patients in the BKPyV-BPAR group more often received less immunosuppressive treatment than recommended by the local rejection management protocol (details in Table 1a), compared to those in the BPAR-only group (19.7% vs. 56.3%, p7 days after the creatinine rise, the mean eGFR increase was only 0.4 ± 7.6 ml/min/1.73m² (p = 0.03). When analyzing graft function, graft loss at 5-years occurred in 3.9% of No-BPAR patients, 27.7% in the BPAR-only group, and 45.0% in the BKPyV-BPAR group (p2 months prior). As BKPyV DNAemia was largely absent in the interim, graft loss due to BKPyVAN appears unlikely. In conclusion, this study shows that patients in whom BPAR was preceded by BKPyV DNAemia experienced both delayed initiation and less intensive rejection treatment, compared to patients with BPAR without prior BKPyV DNAemia. Despite a higher rate of graft loss in this group, the majority of which was attributed to rejection, while no grafts were lost due to BKPyVAN. These findings suggest that conservative rejection management in the context of prior BKPyV needs to be re-evaluated. Further prospective studies are needed to define the optimal management of rejection in the setting of prior BKPyV DNAemia and to better understand the interplay between BKPyV and alloimmunity. Figure 1. Graft outcomes in kidney transplant patients without BPAR, with...